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Conclusion: Our data provide evidence that DENV, CHIKV and
RVF co-circulate in northernMozambique, suggesting that not only
DENV but CHIKV and RVFV, should be considered in the differential
diagnosis of acute febrile syndrome in northern Mozambique.
http://dx.doi.org/10.1016/j.ijid.2016.02.430
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Background: Pakistan is rated among one of the high Leish-
mania prevalent countries. The rising incidence of Leishmania in
Pakistan aremarkedbypoverty, poorhealthcare, inadequate vector
control, refugees, inadequate healthcare system and drug short-
ages. Disease is being reported from all over the country specially
the remote underserved mountainous areas of Sindh, Khyber and
Baluchistan provinces.
To address this Pakistan OneHealth Alliance (POHA) in part-
nership with Ministry of Health Services (MOHS), and partners
undertook, ﬁrst ever, Gap Analysis Study in during April – October
2015. Plan was not only to identify gaps between diagnosis and
management, but also, to help suggest a strategic plan to improve
diagnosis, treatment, control and disease prevention.
Methods & Materials: A multidimensional approach was
adopted to undertake this study. Primarily this was a cross sec-
tional study based on questionnaire survey. Questionnaire were
developed for multiple levels of healthcare system including com-
munity and patients. Data was captured from all over the country
including some of the refugees camps.
Results: Cutaneous Leishmania (CL) is reportable under in
National Health Information Systems. Clear inter provincial differ-
ences exist for disease reporting. 15 districts were found very high
disease incidence. Unfortunately, for this disease there is neither
an exclusive control program or integrated with some other dis-
ease. Only 38% of the facilities surveyed had adequate manpower
and diagnostic facilities for the disease. There existed issues with
availability of efﬁcient detection and response system, staff train-
ing and availability of drugs. In about 50% of facilities there existed
severe drug shortage. Despite the high cost antimony injectionwas
the main line of treatment for CL. This was followed by glucantine
and cryotherapy. These drugs are neither manufactured.
Conclusion: Disease control demand greater political commit-
ment by all stakeholders. Aggressive health education campaigns,
inter sectoral collaboration, proper vector control, drug supply and
preventive measures are desired to address this menace.
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Synthetic DNA encoded antibody prophylaxis
confers rapid protective immunity in vivo
against Chikungunya virus infection
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Background: Chikungunya (CHIKV) disease is a serious emerg-
ing mosquito-transmitted viral infection responsible for epidemic
outbreaks. Currently, no licensed vaccines or therapies are avail-
able against this virus, resulting in signiﬁcant global spread with
concurrent population morbidity.
Methods & Materials: This study describes a novel immune-
based intervention that utilizes in vivo deliver of synthetic DNA
plasmids encoding a monoclonal antibody (mAb) targeting the
CHIKV envelope protein.
Results: Importantly, a single intramuscular injection with a
DNA plasmid expressing an anti-CHIKV mAb produced antibodies
in mice more rapidly than vaccination with CHIKV-Env-encoding
DNA plasmids. DNA-mediated delivery of anti-CHIKV antibodies
neutralizeddiverse clinical isolates in vitro andprotectedmice from
lethal CHIKV challenge.
Conclusion: This study illustrates the ability of antibody-
encoding plasmids to induce rapid protection against CHIKV
highlighting the potential of this novel immunoprophylaxis and
therapeutic applications platform for other emerging infectious
pathogens.
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